Distinct tumour specificity and IL-7 requirements of CD56(-)and CD56(+) subsets of human gamma delta T cells.
gamma delta T cells are believed to recognize tissue injury caused by infections, tumours, as well as chemical and physical agents. The present study was carried out to study the feasibility of the ex vivo expansion of gamma delta T cells from healthy individuals, and to determine their functional capacity against tumours. We selectively expanded the peripheral gamma delta T cells of five donors against a myeloma cell line, XG-7. Under optimal conditions, the resulting bulk cultures comprised about 82% of the gamma delta T cells, more than 90% of which showed the T-cell receptor (TCR)-V gamma 9 delta 2 rearrangement. These gamma delta T-cell cultures exhibited TCR-gamma delta dependent cytotoxicity against different tumour cell lines including Molt-4, BJAB, Epstein-Barr virus (EBV) transformed lymphoid cell lines (LCL), and the nasopharyngeal carcinoma (NPC) cell lines, CNE2 and 915, in addition to the stimulator XG-7. By competitive cytotoxicity assays, the gamma delta T cells demonstrated recognition of at least three distinct target specificities expressed by Molt-4, CNE2 and LCL, respectively, which were related to that expressed by the stimulator XG-7 cells. The recognition of the specificity expressed by XG-7 and Molt-4 was further shown to require the participation of heat shock protein (HSP). The specificity expressed by CNE2 and 915 was preferentially recognized by the CD56 subset of gamma delta T cells, which could be sustained in the presence of interleukin (IL)-7. These results suggested that gamma delta T-cell immunity against tumour cell lines may be acquired in response to other types of tissue injury and, hence, implicates a role for their use in the prevention and treatment of tumours.
Zheng
B
B
Department of Microbiology, The University of Hong Kong, Hong Kong SAR.
Lam
C
C
Im
S
S
Huang
J
J
Luk
W
W
Lau
S Y
SY
Yau
K K
KK
Wong
C
C
Yao
K
K
Ng
M H
MH
D002051:Burkitt Lymphoma / Q000276:immunology / Q000473:pathology; D019002:CD56 Antigen / Q000032:analysis*; D002277:Carcinoma / Q000276:immunology / Q000473:pathology; D002478:Cells, Cultured; D016207:Cytokines / Q000494:pharmacology; D003601:Cytotoxicity Tests, Immunologic; D003602:Cytotoxicity, Immunologic; D004357:Drug Synergism; D005240:Feasibility Studies; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000494:pharmacology; D015851:Interleukin-7 / Q000494:pharmacology* / Q000502:physiology; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000276:immunology / Q000473:pathology; D008213:Lymphocyte Activation; D009101:Multiple Myeloma / Q000276:immunology / Q000473:pathology; D009303:Nasopharyngeal Neoplasms / Q000276:immunology / Q000473:pathology; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000032:analysis*; D011994:Recombinant Proteins / Q000494:pharmacology; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology*; D014407:Tumor Cells, Cultured / Q000276:immunology
D019002:CD56 Antigen; D016207:Cytokines; D007376:Interleukin-2; D015851:Interleukin-7; D016692:Receptors, Antigen, T-Cell, gamma-delta; D011994:Recombinant Proteins